Research on SmacN7 in sensibilization of cisplatin for huam novarian cancer cells

Objective:To explore whether SmacN7 can increase senxitivity of human ovarian cancer cells to cisplatin and its relationship with expression of Caspase-3.Methods:MTT assay and Flat cloning experiment were used to study the control group: cisplatin group(group A,50 μg/L),SmacN7 and cisplatin group(group B,100 μg/L),SmacN7 and cisplatin group(group C,200 μg/L),SmacN7 and cisplatin group(group D),the inhibition rate of cell proliferation and cell colony formation rate were evaluated.Immunocytochemistry was used to detect caspase-3 experssions.Results:When applying cisplatin alone,the proliferation inhibition rate at 24,48 and 72 hours were(6.12±1.16)%,(13.47±1.15)%,and(28.91±1.08)%,respectively.When applying SmacN7(50-200μg/L) combined with cisplatin,with the increase of SmacN7 concentration or the prolongation of treatment time,the proliferation inhibitory rates of cancer cell increased,which were(9.34±1.78)%-(49.81±2.11)%,(25.24 ±2.11)%-(65.54±2.27)%,and(44.45±1.21)%-(82.36±2.19)% respectively at 24,48,and 72 hours.The survival rates of tumor cell decreased significantly,which were(25.13±0.52)%,(21.17±0.55)%,(18.23±0.54)%,and(15.27±0.56)%,respectively.After applying SmacN7 combined with cisplatin,the expression rate of Caspase-3 increased statistically significantly,compared with applying cisplatin alone,there was statistically significant difference when explore by Flat cloning experiments,there was statistically significant difference(P=0.000).Conclusion:SmacN7 can significantly increase the sensitivity of human ovarian cancer cells to cisplatin.